During the Fitbit Q1 earnings call, the company confirmed its focus on digital health regardless of the expected decline in sales numbers. Currently, Fitbit is focusing on its new alliance with Google, wherein the two companies will work together to speed up innovation in the digital health space to provide clear EHRs and precise patient data to help the clinicians.
In a bid to sweeten its deal for Fortis Healthcare, Manipal Health Enterprises has proposed merging of both enterprises that pegs the value of the beleaguered Fortis at Rs. 8,358 crores. The buyout efforts of Manipal have been backed by US private equity firm TPG.
Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that Celgene Corporation has exercised its right to expand its collaboration agreement for the research, development, and commercialization of bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform.
Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.